Open Nav

OrPro Therapeutics Inc.

  • Peter Heifetz, OrPro Therapeutics Inc

Engagement with potential investors and strategic partners

  • Date:Thursday, October 18
  • Time:2:15 PM - 2:30 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:OrPro Therapeutics, Inc. is developing a non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus. The company’s core technology based on the human thioredoxin-1 enzyme was licensed exclusively from National Jewish Health, the leading US respiratory hospital, with key patent-protected improvements (the Theradux® platform) developed internally. OrPro’s technology restricts thioredoxin activity to the epithelial surface allowing topical delivery of a target-selective disulfide reductase with extracellular anti-inflammatory and microbial defense-enhancing properties that is capable of normalizing excess viscosity and stiffness of mucus from the lungs of patients with cystic fibrosis (CF). Lead product ORP-100S may both help existing therapies improve pulmonary function and modify disease progression in patients who are not CFTR-modulator candidates.
  • Company Website:www.orprotherapeutics.com
  • Company HQ City:San Diego
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Peter B. Heifetz, Ph.D.
  • Year Founded:2011
  • Main Therapeutic Focus:Respiratory
  • Lead Product in Development :Monothiol human thioredoxin-1 (ORP-100S/Theradux)
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Additional Information/Comments:CF, a life-threatening genetic disease affecting an estimated 85,000 children and adults worldwide, is the most common inherited lethal condition in populations of Northern European descent. In CF and bronchiectasis (BE), impaired mucus transport and lack of clearance due to obstruction precede the onset of chronic infection and inflammation responsible for morbidity and mortality. Inhaled antibiotics and CF modulator drugs have increased CF life expectancy to age 40 for those newly-diagnosed. However, while modulator use may one day be extended to as many as 80% of CF genotypes with new combination drugs currently in the clinic, even the best-responding patients still suffer declining lung function and are frequently hospitalized for disease exacerbations with many ultimately requiring lung transplantation. A large unmet need therefore exists for effective, mechanism-based mucus-normalizing treatments that may prevent progression to disease symptoms.
  • Previous and Current Investors:Garner Investments, Nerveda
  • Size of Last Investment Round:500000
  • Total Amount Raised to Date, In All Rounds:2300000
Speakers
Peter Heifetz
OrPro Therapeutics Inc
Back